About: Will Simpson

Recent Posts by Will Simpson

PM 360 Recognizes POLARISqb as a 2020 Innovative Startup

PM 360 is one of the leading magazines in the pharmaceutical marketing world, with an audience of marketing decision makers in the pharmaceutical, biotech, and medical device industries. Published monthly, the magazine focuses on leadership as well as, "issues that directly impact critical decision making,including: planning and implementation of cutting edge strategies, trends, the latest technological advances," in their writing.

This year, POLARISqb was honored to be one of eight companies that were named "Innovative Startups" by the magazine, along with Evozyne, Steady Shot, ImmunAI, Exocel, wePool, Conversation Health and Theraneutrics. These companies are working with some of the most advanced technologies such as artificial intelligence, nanotechnology, and synthetic biotech to address medical issues from diabetes to COVID-19, but POLARISqb stands alone as the sole quantum application selected to the list. Having developed a quantum application for designing drugs, we continue to pursue a vastly greater understanding of our chemical universe, identifying molecules that will become treatments and cures for all diseases for all people. Advancements in quantum computers technology continue to speed our work towards a quantum-based platform that provides chemical simulations at many times the speed of current traditional systems.

We are proud to be recognized for our work and innovation in drug discovery for biopharma applications by one of the leading publications on pharmaceutical marketing, a list that has in the past included companies such as H1 who went on to raise over $71M in capital funding and OM1 who raised over $86M, and Sema4 which raised over $240M. POLARISqb looks to be the next in their line of success, and the first quantum alumni of the list to revolutionize the world of biotech and pharmaceuticals.

Accelerating Drug Discovery Through Collaboration
Fujitsu has been working with POLARISqb as we build the first drug discovery platform for use on a quantum computer. See the excerpt from their case study and download the pdf below, or visit their site for more information. From Fujitsu: As has become painfully clear during the COVID-19 pandemic, the development of new drugs…
Read more
BioPharmaTrend.com Names POLARISqb a Notable Biotech Startup

BioPharmaTrend.com is a leading blog covering the pharmaceutical sector with a focus on Artificial Intelligence, Drug Discovery, and the ways that the healthcare sector is changing due to the digital transformation happening within the industry. Having also built an analytics platform for the sector, BioPharmaTrend understands the impact of technology not only from a journalistic standpoint, but from the viewpoint of a tech innovator who has created their own platform. POLARISqb was cited in their recent article, "Pharmaceutical Artificial Intelligence in 2020: The Sector is Heating Up For Investments," alongside leading companies like Xtalpi, Insitro, ImmunAI, Transilico, and others.

In reading the fundraising numbers cited in the article, it is clear that the AI sector truly is heating up in terms of investments. Xtalpi certainly leads the way, having secured $319 million in capital, but other companies have had Series B rounds ranging from $20 million to $150 million in 2020. As we continue to see artificial intelligence become more commercially viable and stable technologies within the sector, the speed with which pharmaceutical achievements are accomplished will become greater, lowering costs and providing access to medical breakthroughs to many patients who may have previously not had treatment options previously. Also, developments within the quantum computing sector are advancing at a meteoric pace, and with these developments come opportunities to apply more advanced computing techniques, as we do in POLARISqb, to help develop novel treatments for diseases that have previously proven difficult to treat or cure. This is one way that we are unique among the companies named in the article, as we were the only company recognized that is utilizing a proven quantum solution within the biopharma sector.

It is for precisely this kind of work that BioPharmaTrend has recognized POLARISqb, as our use of quantum computing to power optimization and annealing processes within drug discovery holds the promise of revolutionizing the timelines for developments of new drugs and treatments. In the article, they identify our, "new drug discovery platform, which combines quantum-inspired technology, machine learning, hybrid quantum mechanics, and molecular mechanics simulations," as a promising development for cutting drug development timelines by up to 90%. The applicability of the POLARISqb system continues to grow, we work to ensure our software stack is agnostic in most respects, meaning that the algorithms can be used on a variety of compute architectures. We are honored to be recognized alongside industry leaders and other startups that are among the vanguard of the use of artificial intelligence in the pharmaceutical sector, and look forward to a future where our technology is able to change the world, providing drug treatments to cure all diseases for all people.

POLARISqb Named One of Seven Pharma Startups to Watch in 2021 by Startus Insights

StartUs Insights, a leading research and consulting group focused on the global startup market, has named POLARISqb one of their "7 Pharma Startups You Should Watch in 2021." StartUs Insights, which works with major international corporations such as Nestle, Lufthansa, and Pharmapack, researches the most promising startup companies from across a wide variety of industries including pharmaceuticals, transportation, healthcare, and logistics

2020 has brought significant challenges in the pharmaceutical sector, and StartUs Insights recognized POLARISqb along with companies that develop novel treatment such as ANA Therapeutics and MRM Health and companies working to develop vaccines and testing such as Ancora.AI and Pulmobiotics. In describing the company, StartUs cited our work that, "combines quantum computing and AI to search through large and unstructured medical datasets,"  as well as recognizing the ability of our software to filter for drug toxicity and other ADMET characteristics of various potential treatment molecules. As we continue to develop our platform to utilize the most advanced quantum computing resources available, our ability to use this technology to target specific proteins and diseases is making the drug discovery process more efficient and accurate.

We are glad to be recognized by StartUs Insights as a leader in the world of quantum drug discovery, as we proceed in our development of tools that will revolutionize the costs and timeframe associated with the development of new drugs and treatments. These technologies will provide greater opportunity for us to achieve the goal set forth in our company motto, to create drug blueprints to treat and cure all diseases for all people.

Recent Comments by Will Simpson

No comments by Will Simpson yet.